ABT vs ISRG
Abbott Laboratories and Intuitive Surgical, side by side.
Prices and company dataas of yesterday's close
- ABTKeep2.3%
Abbott Laboratories pays a 2.3% dividend that it has raised for 54 years in a row, but the stock fell 5.3% over the past five trading days, in step with other medical device makers (down 4.7%).
- ISRGBuy more19%
Intuitive Surgical's report on Oct 20 beat profit forecasts by 19%, and its sales grew 20% over the past year.
Percent return
- ABT−11.81%
- ISRG−21.43%
Nov 11, 2025 to Nov 11, 2026
Where they differ
- Company size: ABT $174B, ISRG $127B.
- Sales growth, 1 yr: ABT +10%, ISRG +20%. ISRG is ahead.
- Price for $1 of next year's profit: ABT $19, ISRG $38. ABT is ahead.
- Profit per $1 of sales: ABT 16¢, ISRG 32¢. ISRG is ahead.
- Cash minus debt: ABT −$27.1B, ISRG +$4.04B. ISRG is ahead.
- Price change, 1 yr: ABT −12%, ISRG −21%. ABT is ahead. S&P 500 +12%.
- How much the price swings: ABT 30%, ISRG 46%. ABT is ahead.
| Measure | ABTAbbott Laboratories | ISRGIntuitive Surgical |
|---|---|---|
| Price and returns | ||
| Price | $109.35 | $449.58 |
| Today | −1.00% | Best in this row: −0.10% |
| 1 month | Best in this row: +10.40% | +6.03% |
| 3 months | +0.28% | Best in this row: +12.05% |
| This year | Best in this row: −10.60% | −20.63% |
| 1 year | Best in this row: −11.81% | −21.43% |
| 5 years | −5.13% | Best in this row: +28.15% |
| From 52-week high | −14.2% | −24.2% |
| How much it swings (90 days) | Best in this row: 30% | 46% |
| Valuation | ||
| Market value | $174B | $127B |
| Price vs last year's earnings | Best in this row: 32.3× | 40.5× |
| Price vs next year's expected earnings | Best in this row: 18.8× | 37.5× |
| Price vs earnings, adjusted for growth | Best in this row: 1.65× | 2.34× |
| Price to sales | Best in this row: 4.0× | 13.6× |
| Price vs cash it brings in | Best in this row: 28.2× | 43.6× |
| Company value vs operating profit | Best in this row: 19.0× | 34.2× |
| Growth | ||
| Revenue growth, 1 year | +10.0% | Best in this row: +20.4% |
| Revenue growth a year, last 3 years | +0.5% | Best in this row: +17.4% |
| Earnings per share growth, last year | −53.4% | Best in this row: +20.4% |
| Earnings per share growth expected next year | +7.6% | Best in this row: +10.9% |
| Profitability | ||
| Kept from sales after making the product | 57.2% | Best in this row: 66.6% |
| Kept as operating profit | 15.7% | Best in this row: 31.7% |
| Kept as final profit | 9.7% | Best in this row: 25.5% |
| Kept as spare cash | 14.0% | Best in this row: 31.1% |
| Profit on shareholders' money | 9.1% | Best in this row: 17.9% |
| Profit on all money put in | 6.9% | Best in this row: 24.0% |
| Balance sheet | ||
| Net cash (cash minus debt) | −$27.1B | Best in this row: $4.04B |
| Debt for each $1 of shareholders' money | 0.61× | – |
| Short-term assets per $1 of bills due | 1.45× | Best in this row: 3.33× |
| Dividend yield | 2.29% | – |
| Share of profit paid as dividends | 94% | – |
| Our readPro | ||
| Our call | Keep | Buy more |
| Why | Abbott Laboratories pays a 2.3% dividend that it has raised for 54 years in a row, but the stock fell 5.3% over the past five trading days, in step with other medical device makers (down 4.7%). | Intuitive Surgical's report on Oct 20 beat profit forecasts by 19%, and its sales grew 20% over the past year. |
| Where the price sits | in the full report | in the full report |
| Our overall score (out of 100) | 57 | Best in this row: 66 |
| Our value score | Best in this row: 82 | 38 |
| Our growth score | 33 | Best in this row: 76 |
| Our quality score | 68 | Best in this row: 83 |
| Our price trend score | Best in this row: 63 | 62 |
| Earnings and analysts | ||
| Analyst consensus | Buy | Buy |
| To average analyst target | +11.5% | Best in this row: +12.2% |
| Average analyst target | $121.94 | $504.22 |
| Analysts rating it a buy | Best in this row: 82% | 77% |
| Buy ratings added, 3 months | +2 | +2 |
| Analysts covering | 17 | 19 |
ISRG: our only Buy more, with faster sales growth
Our pick of these: Intuitive Surgical
Sales growth +20.4% vs +10.0%
ABT +10.0%, ISRG +20.4%.Keeps 31.7% of sales as operating profit, vs 15.7%
ABT 15.7%, ISRG 31.7%.Where it loses: ABT has a better past year, −11.8% vs −21.4%
Cover this stock to see the full report
The call, its reasons and what would change it are free for everyone. The price zones, the whole brief and how the call has moved come with covering a stock. Use one of your three covered slots, or go Pro for every stock.
Prices as of yesterday, 3:59 PM ET. A view, not advice.